Will pharmacogenomics alter the role of patents in drug development?

Pharmacogenomics

Volumn 3, Issue 5, 2002, Pages 571-574

  Eisenberg, Rebecca S ^a  

^a UNIVERSITY OF MICHIGAN LAW SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; EDITORIAL; GENOTYPE; HUMAN; LICENCE; PATENT; PHARMACOGENOMICS; POSTMARKETING SURVEILLANCE; PRESCRIPTION;

HUMANS; PATENTS; PHARMACOGENETICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036739552     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.5.571     Document Type: Editorial

References (5)

1. Cohen WM, Nelson RR, Walsh JP: Protecting their intellectual assets: appropriability conditions and why US manufacturing firms patent (or not). NBER Working Paper No. 7552. Nat'l Bureau of Econ. Res. Cambridge, MA, USA (2000).
2. Anand G: Big drug makers try to postpone custom regimens. Wall Street Journal, June 18 (2001).
3. US Code § 321 (g) (1)(B).
4. Washington Legal Foundation v. Friedman, 13 F. Supp.2d 51 D.D.C. (1998).
5. Lesko LJ, Woodcock J: Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J. 2, 20-24 (2002).